Summary The effect of the month of diagnosis on survival was investigated in two series of unilateral invasive breast cancer, of which one comprised 95% of all such histologically diagnosed breast carcinomas in the city of Turku, Finland, in 1945 to 1965, and the other 94% of all such carcinomas diagnosed in 1980 to 1984 (n = 337). If the histological diagnosis was made in January, February, or August to October in 1945-65, or in July to September in 1980-84, mortality in breast cancer was greater than if the diagnosis was made during the rest of the year (P = 0.03 and 0.009, respectively). Cancers diagnosed during the unfavourable months had more tumour necrosis in both series, and higher mitotic count and larger tumour size in the 1945-65 series. The number of diagnosed cases was usually less than the median during the months associated with unfavourable prognosis. Hypotheses to explain the altering prognosis by the month of diagnosis include seasonal hormonal changes and social factors.
The season of initial discovery of tumour has recently been described to be an independent variable predicting survival in breast cancer , and women who detect their breast cancer in spring or summer were found to have more favourable survival as compared with those detecting their tumour at other seasons of the year. It has been suggested that the season of first detection of breast cancer may reflect seasonal changes in hormone dependent growth .
In the present study we evaluated the effect of the month of diagnosis on prognosis of breast cancer in two series with different length of follow-up from the same city. The results show that breast cancers diagnosed in different months of the year carry somewhat different prognosis, and the possible explanations for this are explored.
Materials and methods

Patients
During the time period from 1945 to 1965, 461 cases of female breast cancer were histologically diagnosed in the city of Turku in South-Western Finland. The patients were collected from the files of the Department of Pathology, University of Turku, the Turku University Central Hospital, the City Hospital of Turku, and the Finnish Cancer Registry, which was founded in 1952. Twenty-two patients were treated elsewhere, were lost to follow-up, or had insufficient clinicopathologic data, and women with either intraductal (n = 15) or bilateral breast cancer (n = 23) were The size of the S phase fraction (SPF) was determined from DNA histograms produced by flow cytometry as described in detail elsewhere (Toikkanen et al., 1989 (Cox, 1972) . All P-values are two-tailed.
The month when the first symptoms or signs caused by breast cancer were first noticed was retrieved from the hospital records (available in 681 cases), but the date of the pathologist's report was preferred in statistical calculations, because it was always available and exactly known.
Results
Survival corrected for intercurrent deaths by the month of diagnosis, shown in Table I Jan-Feb/Aug-Sept-Oct (n = 108); The rest of the months (n = 158). P = 0.02. tended to be significant also among women without axillary nodal metastases (pN0, P = 0.06, P = 131), but not among the node positive ones (pN +, P = 0.45, N = 185). Except for January, the number of women diagnosed to have breast cancer was lower than the median during the months associated with poorer survival (median = 33, Table I ).
Mortality in breast cancer was greater if the diagnosis was made in July to September than during the rest of the year in 1980-84 (P = 0.009, n = 337). Survival was significantly inferior among both premenopausal and postmenopausal women (P = 0.05, n = 65 and 0.04, n = 272, respectively, Figure 2 ), but not among women with axillary nodal metastases (pN +, P = 0.26, n = 134) or among those without (pN0, P = 0.29, 162). The number of cases diagnosed during these 3 months was less than the median (median = 29, Table  I ). Survival was particularly good if the diagnosis was made in November (P = 0.02 as compared with the the rest of the year).
Cancers diagnosed during the months associated with less favourable outcome had more extensive tumour necrosis (P = 0.03 in 1945-65, and 0.02 in 1980-84, (Cohen et al., 1983 ). Melatonin, the major hormone of the pineal gland, has been shown to inhibit the growth of mammary tumours in animal models of human breast cancer, and also the estrogenresponsive human breast cancer cell line MCF-7 in culture in physiological concentrations (Hill & Blask, 1988) . On the other hand, melatonin has been reported to increase estrogen receptor binding activity in MCF-7 cells (Danforth et al., 1983) . Mason et al. (1990) ing light in either of the two series, no difference is found (P =0.51 in the 1980-84 series, and 0.95 in the 1945-65 series). Furthermore, there was no difference in mortality from breast cancer in either series if any 6-month period was compared with the rest of the year. The number of diagnosed cases was usually less than the median during the months associated with unfavourable prognosis. If the months with less than the median of diagnosed cases are tested against the months with cases more than the median, the months with more diagnoses are associated with better survival in the 1980-84 series (P = 0.05), but not in the 1945-65 series (P = 0.26). The smaller number of cancers detected during the months associated with greater mortality, and the finding of more cancers with adverse prognostic factors, with a large primary tumour size, a high mitotic count, and extensive tumour necrosis (Table II) , might suggest that women with less aggressive cancers may postpone their contact with the medical personnel longer, and do not seek for treatment during the summer holidays or at the Christmas time, which are popular holiday periods. However, we find no significant difference in the duration of symptoms or signs caused by breast cancer preceding the diagnosis between the unfavourable months and the rest of the year in either series, nor between June to September and October to December in the 1980-84 series.
In the Auckland series ) the months associated with longer survival were October to January, which corresponds to April to July in the Northern Hemisphere. Unlike in the present series the month of initial tumour detection was primarily recorded in the New Zealand series, and their median delay to histological diagnosis was about 2 months, and the mean delay about 3 months . If the time lag between tumour detection and diagnosis is assumed to be from 2 to 3 months, according to Auckland data cancers diagnosed histologically in June to September or in July to October in the Northern Hemisphere should be associated with favourable prognosis. In the Turku data the opposite is found, cancers diagnosed in June to September or in July to October have inferior prognosis (P = 0.02 and 0.06, respectively, in the 1980-84 series). In the New Zealand data the lowest mean monthly breast tumour progesterone receptor concentrations were found in samples taken in August and September (late winter, Holdaway et al., 1990) . These apparently contradictory results may not, however, refute the hormonal hypothesis, because racial factors may be of importance, and the seasonal changes in lightness are considerably greater in Turku (latitude 60°) than in Auckland (latitude 37°).
Some breast cancers are found incidentally by the medical personnel or in screening, and in their detection seasonal hormonal factors are likely to have less importance. The frequency of such cancers is known only for our 1980-84 series, where 38 breast carcinomas were found when the breasts were investigated by a nurse in conjunction with screening for uterine cervical cancer, and further 49 cancers were incidentally found by medical personnel. If the screendetected or both screen-detected and the incidentally found cancers are removed from the survival analysis, cancers diagnosed in July to September still have inferior prognosis (P = 0.008 and 0.047, respectively), and less cancers than the median are still diagnosed in July, August and September.
In accordance with the present data, Jacobson and Janerich (1977) found using the New York State Cancer Registry tumour ER content to be ten times higher in May than in September, May to have the highest frequency of tumour diagnosis, and August, September and December to have the lowest. On the other hand, Hrushesky et al. (1979) from Minneapolis found ER content to be higher in late autumn than in spring, the month with the highest concentrations was November.
In summary, prognosis of breast cancer was dependent on the month of diagnosis, cancers diagnosed in July to September had poorer prognosis. In a multivariate analysis the season of breast cancer diagnosis was not an independent prognostic factor. The reasons for the altering prognosis by the month of the diagnosis remain speculative, but more cancers with less adverse prognostic features were detected at other times of the year.
